Principal Financial Group Inc. boosted its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 17.0% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 208,836 shares of the company's stock after acquiring an additional 30,392 shares during the quarter. Principal Financial Group Inc. owned 0.26% of Viridian Therapeutics worth $2,815,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Amalgamated Bank boosted its stake in shares of Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company's stock valued at $34,000 after purchasing an additional 840 shares during the period. Foresite Capital Management VI LLC bought a new stake in Viridian Therapeutics during the 4th quarter valued at $38,000. AlphaQuest LLC boosted its position in Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares during the period. GAMMA Investing LLC grew its holdings in Viridian Therapeutics by 3,892.9% in the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company's stock worth $114,000 after acquiring an additional 8,214 shares during the last quarter. Finally, Summit Investment Advisors Inc. increased its position in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the period.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on VRDN. Royal Bank Of Canada dropped their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. JMP Securities lowered their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reaffirmed a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. The Goldman Sachs Group decreased their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $37.56.
Read Our Latest Report on VRDN
Viridian Therapeutics Stock Up 3.0%
Shares of VRDN stock traded up $0.50 on Monday, hitting $17.02. The stock had a trading volume of 275,435 shares, compared to its average volume of 1,134,122. The company has a quick ratio of 19.49, a current ratio of 19.49 and a debt-to-equity ratio of 0.05. The company has a market cap of $1.39 billion, a PE ratio of -4.42 and a beta of 0.39. The business has a 50 day moving average price of $14.80 and a 200 day moving average price of $15.31. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $27.20.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.61% and a negative net margin of 102,092.39%. Viridian Therapeutics's quarterly revenue was up .0% compared to the same quarter last year. Research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Featured Articles
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
